Sandra M Swain

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Ongoing adjuvant trials with trastuzumab in breast cancer
    Antoinette R Tan
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20889, USA
    Semin Oncol 30:54-64. 2003
  2. ncbi request reprint Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer
    Jennifer A Low
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20889 5015, USA
    J Clin Oncol 23:2726-34. 2005
  3. ncbi request reprint Aromatase inhibitors--a triumph of translational oncology
    Sandra M Swain
    N Engl J Med 353:2807-9. 2005
  4. ncbi request reprint A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancer
    Janice M Walshe
    Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Institutes of Health, Bethesda, MD 20889, USA
    Clin Breast Cancer 6:535-9. 2006
  5. ncbi request reprint The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review
    S M Swain
    National Institutes of Health, Department of Health and Human Services, 8901 Wisconsin Avenue, Building 8, Room 5101, Bethesda, MD 20889 5105, USA
    J Cancer Res Clin Oncol 130:1-7. 2004
  6. ncbi request reprint Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer
    Sandra M Swain
    National Cancer Institute, Bethesda, MD, USA
    J Natl Cancer Inst 96:516-23. 2004
  7. ncbi request reprint Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials
    Sandra M Swain
    National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20889, USA
    Cancer 97:2869-79. 2003
  8. ncbi request reprint Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer
    W J Gradishar
    Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Ann Oncol 16:1297-304. 2005
  9. ncbi request reprint Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer
    Antoinette R Tan
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20889, USA
    Clin Cancer Res 10:5038-47. 2004
  10. pmc Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer
    Sherry X Yang
    National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 28:2974-81. 2010

Detail Information

Publications61

  1. ncbi request reprint Ongoing adjuvant trials with trastuzumab in breast cancer
    Antoinette R Tan
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20889, USA
    Semin Oncol 30:54-64. 2003
    ..For now, the use of trastuzumab as adjuvant therapy is still investigational, but its integration has tremendous potential to improve treatment outcomes in patients with primary breast cancer...
  2. ncbi request reprint Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer
    Jennifer A Low
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20889 5015, USA
    J Clin Oncol 23:2726-34. 2005
    ..In a phase II trial, we evaluated the efficacy and safety of ixabepilone in women with metastatic and locally advanced breast cancer...
  3. ncbi request reprint Aromatase inhibitors--a triumph of translational oncology
    Sandra M Swain
    N Engl J Med 353:2807-9. 2005
  4. ncbi request reprint A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancer
    Janice M Walshe
    Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Institutes of Health, Bethesda, MD 20889, USA
    Clin Breast Cancer 6:535-9. 2006
  5. ncbi request reprint The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review
    S M Swain
    National Institutes of Health, Department of Health and Human Services, 8901 Wisconsin Avenue, Building 8, Room 5101, Bethesda, MD 20889 5105, USA
    J Cancer Res Clin Oncol 130:1-7. 2004
    ..There are also numerous possibilities for dexrazoxane in other clinical situations, which must be addressed in future trials...
  6. ncbi request reprint Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer
    Sandra M Swain
    National Cancer Institute, Bethesda, MD, USA
    J Natl Cancer Inst 96:516-23. 2004
    ....
  7. ncbi request reprint Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials
    Sandra M Swain
    National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20889, USA
    Cancer 97:2869-79. 2003
    ....
  8. ncbi request reprint Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer
    W J Gradishar
    Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Ann Oncol 16:1297-304. 2005
    ....
  9. ncbi request reprint Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer
    Antoinette R Tan
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20889, USA
    Clin Cancer Res 10:5038-47. 2004
    ..The purpose of this study was to determine the toxicities and characterize the pharmacokinetics of docetaxel and flavopiridol in patients with metastatic breast cancer...
  10. pmc Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer
    Sherry X Yang
    National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 28:2974-81. 2010
    ....
  11. ncbi request reprint Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes
    Neelima Denduluri
    Breast Cancer Section, Medical Oncology Branch and Biostatistics, Office of the Clinical Director, Center for Cancer Research, National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, Bethesda, MD, USA
    J Clin Oncol 25:3421-7. 2007
    ..Ixabepilone was evaluated for efficacy and safety in a phase II clinical trial for women with metastatic breast cancer...
  12. ncbi request reprint Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor
    Antoinette R Tan
    Cancer Therapeutics Branch, Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20889, USA
    J Clin Oncol 22:3080-90. 2004
    ....
  13. ncbi request reprint Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer
    Neelima Denduluri
    Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Heath, Bldg 8, Rm 5101, 8901 Wisconsin Ave, Bethesda, MD 20889 5015, USA
    Invest New Drugs 25:63-7. 2007
    ..Although ixabepilone was well-tolerated, the dose of 8-10 mg/m(2) daily for 3 days is not an effective therapy in metastatic breast cancer previously exposed to taxanes...
  14. ncbi request reprint A prospective study of adjuvant CMF in males with node positive breast cancer: 20-year follow-up
    Janice M Walshe
    Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20889, USA
    Breast Cancer Res Treat 103:177-83. 2007
    ..To determine the long-term overall survival of male patients with stage II node positive breast cancer treated with adjuvant chemotherapy...
  15. doi request reprint Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer
    Chia C Portera
    Medical Oncology Branch, National Cancer Institute, Bethesda, MD, USA
    Clin Cancer Res 14:2710-6. 2008
    ..To evaluate safety and efficacy of trastuzumab with pertuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who had progressive disease on trastuzumab-based therapy...
  16. ncbi request reprint Circulating biomarkers of bevacizumab activity in patients with breast cancer
    Neelima Denduluri
    Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Heath, Bethesda, Maryland, USA
    Cancer Biol Ther 7:15-20. 2008
    ..Tumor samples were evaluated for VEGFR-2 mutations before and after bevacizumab...
  17. ncbi request reprint Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel
    Michael C Cox
    Clinical Pharmacology Research Core, National Cancer Institute, Bethesda, Maryland 20889, USA
    Clin Cancer Res 12:4636-40. 2006
    ..This study examines the influence of garlic supplementation on the pharmacokinetics of docetaxel, a CYP3A4 substrate...
  18. ncbi request reprint Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer
    Suparna Bonthala Wedam
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, 8901 Wisconsin Avenue, Building 8, Rm 5101, Bethesda, MD 20889 5015, USA
    J Clin Oncol 24:769-77. 2006
    ..Bevacizumab, a recombinant humanized monoclonal antibody to VEGF, was administered to previously untreated patients to evaluate parameters of angiogenesis...
  19. doi request reprint The influence of a gene expression profile on breast cancer decisions
    Leonard R Henry
    Division of Surgical Oncology, Department of Surgery, National Naval Medical Center, Bethesda, Maryland, USA
    J Surg Oncol 99:319-23. 2009
    ..We investigated the impact of the RS on actual chemotherapy administration and the effect of the assay on a panel of breast oncology experts...
  20. ncbi request reprint Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancer
    Sherry X Yang
    Cancer Therapeutics Branch in Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20889, USA
    Clin Cancer Res 11:6226-32. 2005
    ....
  21. pmc Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer
    Sherry X Yang
    National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 14:5893-9. 2008
    ..To identify biomarkers and gene expression profile signatures to distinguish patients with partial response (PR) from those with stable disease (SD) and progressive disease (PD)...
  22. ncbi request reprint A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer
    Peter F Lebowitz
    Medical Oncology Clinical Research Unit, Cancer Therapeutics Branch, Laboratory of Pathology, Biostatistics and Data Management, and Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 10:6764-9. 2004
    ..This study evaluated the toxicity and efficacy of docetaxel/capecitabine as neoadjuvant treatment for stage 2/3 breast cancer...
  23. ncbi request reprint A pilot study to evaluate the vascular endothelial growth factor receptor tyrosine kinase inhibitor AZD2171 and chemotherapy in locally advanced and inflammatory breast cancer
    Neelima Denduluri
    Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Clin Breast Cancer 6:460-3. 2005
  24. ncbi request reprint Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experience
    Arpi Thukral
    Medical Oncology Branch, Molecular Imaging Program, and Biostatistics and Data Management Section, Center for Cancer Research, NCI, and Diagnostic Radiology Department, Warren G Magnuson Clinical Center, NIH, Bethesda, MD 20889 5015, USA
    Radiology 244:727-35. 2007
    ....
  25. ncbi request reprint Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone
    James J Lee
    Cancer Therapeutics Branch, Medical Oncology Clinical Research Unit, and Biostatistics and Data Management Section, Center for Cancer Research, Cancer Therapy Evaluation Program, National Institutes of Health, Bethesda, MD 20889 5015, USA
    J Clin Oncol 24:2084-91. 2006
    ....
  26. ncbi request reprint Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer
    Janice M Walshe
    Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research National Cancer Institute, National Institutes of Health, Bethesda, MD 20889, USA
    J Clin Oncol 24:5769-79. 2006
    ....
  27. ncbi request reprint Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarray
    Sherry X Yang
    National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Oncol Rep 17:281-7. 2007
    ..20 and 0.31; all P>0.15). The significant association of eIF4E with VEGF and cyclin D1 in multiple tumors supports a role for eIF4E in translational regulation of proteins related to angiogenesis and growth...
  28. ncbi request reprint Ductal carcinoma in situ, complexities and challenges
    Gregory D Leonard
    Cancer Therapeutics Branch, National Cancer Institute, Bethesda, MD 20889 5105, USA
    J Natl Cancer Inst 96:906-20. 2004
    ..Ongoing and recently completed studies should provide information on outcomes in patients treated with lumpectomy alone and on the effectiveness of aromatase inhibitors as an alternative to tamoxifen...
  29. ncbi request reprint Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy
    Jennifer A Low
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bldg 8, Rm 5101, 8901 Wisconsin Ave, Bethesda, MD 20889 5015, USA
    J Clin Oncol 22:4067-74. 2004
    ..To determine long-term event-free (EFS) and overall survival (OS) for patients with stage III breast cancer treated with combined-modality therapy...
  30. ncbi request reprint Clinical aspects of inflammatory breast cancer
    Janice M Walshe
    Breast Cancer Section, Medical Oncology Branch, Centre for Cancer Research, National Cancer Institute, National Institute of Health, MD 20889, USA
    Breast Dis 22:35-44. 2005
    ..This review addresses the historical milestones and clinical characteristics involved in the differentiation of IBC and briefly discusses the emerging molecular data that may facilitate the distinction of IBC from LABC...
  31. ncbi request reprint Primary systemic chemotherapy for inflammatory breast cancer
    Sarah Sinclair
    Department of Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Cancer 116:2821-8. 2010
    ..A better understanding of the complex biology of IBC is needed for the development of additional targeted agents to further improve outcomes for patients with this aggressive form of breast cancer...
  32. doi request reprint p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer
    Sherry X Yang
    National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bldg 37 Rm 1048, Bethesda, MD 20892, USA
    Int J Oncol 38:1445-52. 2011
    ..Our data suggest that baseline p53, apoptosis and HER2 are each significantly associated with outcome in patients who received bevacizumab plus chemotherapy...
  33. ncbi request reprint CA 125 elevation in breast cancer: a case report and review of the literature
    Gregory D Leonard
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Breast J 10:146-9. 2004
    ..Further information on CA 125 in breast cancer is required to delineate its role in the management of this disease...
  34. doi request reprint Twenty-five year results of the national cancer institute randomized breast conservation trial
    Nicole L Simone
    Radiation Oncology Branch, National Cancer Institute NIH, Building 10 CRC, Room B2 3500, 10 Center Drive, Bethesda, MD 20892, USA
    Breast Cancer Res Treat 132:197-203. 2012
    ..Further studies are required to delineate patients at higher risk for these events, and prolonged follow up should be encouraged after treatment for all women...
  35. ncbi request reprint Peripheral neuropathy induced by microtubule-stabilizing agents
    James J Lee
    Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20889 5015, USA
    J Clin Oncol 24:1633-42. 2006
    ....
  36. ncbi request reprint Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR)
    James J Lee
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20889 5015, USA
    Semin Oncol 32:S22-6. 2005
    ..The development of these novel agents may evade MDR and may improve the outcome of patients with breast cancer...
  37. doi request reprint Pazopanib for the treatment of breast cancer
    Laleh Amiri-Kordestani
    National Cancer Institute, 10 Center Drive, 12N226, Bethesda, MD, USA
    Expert Opin Investig Drugs 21:217-25. 2012
    ..Pazopanib is a multitargeted tyrosine kinase inhibitor that is currently approved for the treatment of patients with advanced renal cell carcinoma (RCC)...
  38. ncbi request reprint A novel case of bisphosphonate-related osteonecrosis of the torus palatinus in a patient with metastatic breast cancer
    Matthew L Goldman
    Breast Cancer Section, Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20889, USA
    Oncology 71:306-8. 2006
    ..This case demonstrates that patients with a torus palatinus may be at high risk for osteonecrosis, and reinforces the need for good oral hygiene and frequent dental examination while receiving bisphosphonate therapy...
  39. ncbi request reprint Concepts and clinical trials of dose-dense chemotherapy for breast cancer
    Jennifer A Orzano
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Department of Health and Human Services, Bethesda, MD, USA
    Clin Breast Cancer 6:402-11. 2005
    ..The strengths and limitations of CALGB 9741 will then be discussed before the presentation of future directions of research and recommendations for clinical practice today...
  40. ncbi request reprint Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms
    Antoinette R Tan
    Center for Cancer Research, Developmental Therapeutics Program, and Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 20:4074-82. 2002
    ..To define the maximum-tolerated dose (MTD), dose-limiting toxicity, and pharmacokinetics of the cyclin-dependent kinase inhibitor flavopiridol administered as a daily 1-hour infusion every 3 weeks...
  41. ncbi request reprint Ixabepilone for the treatment of solid tumors: a review of clinical data
    Neelima Denduluri
    National Cancer Institute, National Institutes of Health, Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, 10 Center Drive, Room 12N226, Bethesda, Maryland 20892, USA
    Expert Opin Investig Drugs 17:423-35. 2008
    ..However, due to limitations of these agents, newer more effective cytotoxic agents are necessary. Ixabepilone, an epothilone B analog, is a novel microtubule stabilizing agent...
  42. ncbi request reprint Emerging drugs to replace current leaders in first-line therapy for breast cancer
    Michael C Cox
    National Cancer Institute National Institutes of Health, Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, Bethesda, MD, USA
    Expert Opin Emerg Drugs 11:489-501. 2006
    ..These agents have increased excitement in the treatment of breast cancer and stand on the forefront of a potential improvement in quality of life and treatment options for patients afflicted with this deadly disease...
  43. ncbi request reprint A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer
    Sheri K Dennison
    Walter Reed Army Medical Center, 6900 Georgia Ave NW, Washington, DC 20307, USA
    Invest New Drugs 25:545-51. 2007
    ..The combination of gefitinib and docetaxel is an active regimen in patients with previously untreated metastatic breast cancer, with a clinical benefit rate and toxicity profile in the range of that reported for docetaxel alone...
  44. ncbi request reprint Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer
    Nicole J McCarthy
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20889, USA
    Clin Cancer Res 8:3857-62. 2002
    ....
  45. doi request reprint Cardiac toxicity in breast cancer survivors: review of potential cardiac problems
    Brian R J Healey Bird
    Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, MD, USA
    Clin Cancer Res 14:14-24. 2008
    ..This review examines the cardiac toxicity of adjuvant therapy, monitoring for early changes and existing guidelines for monitoring cardiac function in patients with breast cancer...
  46. ncbi request reprint Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor
    Erin R Lepper
    Clinical Pharmacology Research Core, Medical Oncology Clinical Research Unit, and Cancer Therapeutics Branch, National Cancer Institute, 9000 Rockville Pike, Building 10, Room 5A01, Bethesda, MD 20892, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 796:181-8. 2003
    ..2% and 2.13 to 5.10%, respectively, for three different sets of quality control samples. The developed method was successfully applied to study the pharmacokinetics of erlotinib in a cancer patient at the recommended daily dose of 150 mg...
  47. doi request reprint Pertuzumab : evolving therapeutic strategies in the management of HER2-overexpressing breast cancer
    Ciara C O'Sullivan
    Medical Oncology Branch, National Institutes of Health, Bethesda, MD, USA
    Expert Opin Biol Ther 13:779-90. 2013
    ..The efficacy of pertuzumab and trastuzumab in conjunction with chemotherapy is currently being evaluated in the adjuvant setting...
  48. ncbi request reprint Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy
    Antoinette R Tan
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD20889, USA
    Semin Oncol 29:77-85. 2002
    ..The interruption of the cell cycle through modulation of CDKs with an agent such as flavopiridol has potential therapeutic efficacy, especially in combination with chemotherapy...
  49. pmc Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells
    Kip A West
    Cancer Therapeutics Branch, Cell and Cancer Biology Branch, National Cancer Institute, Bethesda, Maryland 20889, USA
    J Clin Invest 111:81-90. 2003
    ..Redundant Akt activation by nicotine and NNK could contribute to tobacco-related carcinogenesis by regulating two processes critical for tumorigenesis, cell growth and apoptosis...
  50. ncbi request reprint Cardiovascular complications of breast cancer therapy
    Sandra M Swain
    Washington Cancer Institute, Washington Hospital Center, Washington, DC, USA
    Clin Adv Hematol Oncol 6:247-8, 282. 2008
  51. doi request reprint Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy
    Julia D Wulfkuhle
    Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia 20110, USA
    J Proteome Res 7:1508-17. 2008
    ..Analysis of biopsy material from clinical trials for targeted therapeutics demonstrates the feasibility and utility of comprehensive signal pathway activation profiling for molecular analysis...
  52. doi request reprint Locally advanced and inflammatory breast cancer
    Stephen Chia
    Department of Medical Oncology, British Columbia Cancer Agency, 600 West 10th Ave, Vancouver, British Columbia, Canada
    J Clin Oncol 26:786-90. 2008
  53. ncbi request reprint The heart of the matter
    Chia C Portera
    J Clin Oncol 25:3794-6. 2007
  54. ncbi request reprint Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast can
    Elizabeth Tan-Chiu
    National Surgical Adjuvant Breast and Bowel Project NSABP, University of Pittsburgh, PA, USA
    J Clin Oncol 23:7811-9. 2005
    ..Trastuzumab is effective in treating human epidermal growth factor receptor 2 (HER2) -positive breast cancer, but it increases frequency of cardiac dysfunction (CD) when used with or after anthracyclines...
  55. ncbi request reprint Rationale and clinical trial design for evaluating gemcitabine as neoadjuvant and adjuvant therapy for breast cancer
    Eleftherios P Mamounas
    Cancer Center, Aultman Health Foundation, Canton, OH 44710, USA
    Clin Breast Cancer 4:S121-6. 2004
    ..These trials will be important in establishing a role for this agent in the adjuvant setting and will hopefully lead to the development of more effective adjuvant chemotherapy regimens in the future...
  56. ncbi request reprint A step in the right direction
    Sandra M Swain
    J Clin Oncol 24:3717-8. 2006
  57. ncbi request reprint Contralateral breast cancer: where does it all begin?
    Suparna Bonthala Wedam
    J Clin Oncol 23:4585-7. 2005
  58. ncbi request reprint Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Edward H Romond
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    N Engl J Med 353:1673-84. 2005
    ..We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent trastuzumab in women with surgically removed HER2-positive breast cancer...
  59. ncbi request reprint Oophorectomy in carriers of BRCA mutations
    Sen H Zhuang
    N Engl J Med 347:1037-40; author reply 1037-40. 2002
  60. ncbi request reprint Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management
    Sandra M Swain
    Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA
    Clin Adv Hematol Oncol 6:455-67. 2008
    ..This article provides an overview of the incidence, characteristics, and management of MTI-associated neurotoxicities for known vinca alkaloids and taxanes, as well as newer agents, such as vinflunine and ixabepilone...
  61. doi request reprint The epothilones: translating from the laboratory to the clinic
    James J Lee
    Section of Medical Oncology, Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut, USA
    Clin Cancer Res 14:1618-24. 2008
    ..The development of predictive markers for epothilone chemotherapy is highly desired to provide more tailored therapy for patients with cancer...